Our ultimate goal is to develop mechanism-based pharmacokinetic (PK)-pharmacodynamic (PD) models to characterize and to predict CNS drug responses in both physiologic and pathologic conditions. To this end, it is essential to have information on the biophase pharmacokinetics, because these may significantly differ from plasma pharmacokinetics. It is anticipated that biophase kinetics of CNS drugs are strongly influenced by transport across the blood-brain barrier (BBB). The special role of microdialysis in PK/PD modeling of CNS drugs lies in the fact that it enables the determination of free-drug concentrations as a function of time in plasma and in extracellular fluid of the brain, thereby providing important data to determine BBB transport characteristics of drugs. Also, the concentrations of (potential) extracellular biomarkers of drug effects or disease can be monitored with this technique. Here we describe our studies including microdialysis on the following: (1) the evaluation of the free drug hypothesis; (2) the role of BBB transport on the central effects of opioids; (3) changes in BBB transport and biophase equilibration of anti-epileptic drugs; and (4) the relation among neurodegeneration, BBB transport, and drug effects in ParkinsonÕs disease progression.
INTRODUCTION
The biophase kinetics of a CNS drug are an important determinant in the time course and intensity of its CNS effects. Apart from plasma pharmacokinetics (PKs), mechanisms that govern CNS biophase kinetics include the rate and extent of blood-brain barrier (BBB) transport 1, 2 and the kinetics of processes of distribution and elimination within the brain. To date, a few studies have applied mechanism-based PK-pharmacodynamic (PD) modeling to in vivo data [3] [4] [5] [6] based on only plasma PKs. However, especially for CNS drugs, biophase PKs may differ significantly from plasma PKs, because BBB transport and brain distribution often do not occur instantaneously and to a full extent. 1, 7, 8 Biophase PKs should, therefore, be taken into consideration in mechanism-based PK/PD modeling. BBB transport 9 is related to BBB functionality and occurs by passive diffusion, as well as by active transport. Active transport occurs by many membrane transporters, 10, 11 such as the P-glycoprotein (Pgp) 12, 13 and the multidrug resistance-associated proteins (MRPs).
14-16 BBB functionality is dynamically controlled 17, 18 by blood components and the surrounding brain cells by direct contact or indirectly by their extracellular products. Thus, BBB functionality may vary among different physiologic, pathologic, and chronic drug treatment conditions. 19, 20 It is anticipated that such variations in BBB functionality will ultimately affect the biophase kinetics of CNS drugs.
In vivo microdialysis is a valuable technique, because it enables the determination of the free drug in plasma and its concentrations in extracellular fluid (ECF) the brain as a function of time. Herewith, it provides important information for the determination of BBB transport and brain distribution. A prerequisite for this application is that BBB transport characteristics will not be significantly influenced by microdialysis probe implantation and presence in the brain. This was an initial concern. But based on a series of studies performed to validate the usefulness of intracerebral microdialysis in measurements of passive, as well as active, BBB transport, 8, 21, [26] [27] [28] this prerequisite appears to hold, provided that this technique is used under wellcontrolled surgical and experimental conditions. 29 Here, in short, the main principles of mechanism-based PK/PD modeling of CNS active drugs are described, including arguments for the need to include biophase kinetics, followed by the description of factors that govern biophase kinetics of CNS drugs. Then, a short overview is given on current projects in rats that include investigations of different aspects of biophase equilibration of drug, which are the evaluation of the free drug hypothesis, the role of BBB transport on the central effects of opioids, changes in BBB transport and biophase equilibration of anti-epileptic drugs, and the relation among neurodegeneration, BBB transport, and drug effects in ParkinsonÕs disease progression.
Mechanism-Based PK-PD Modeling of CNS Active Drugs
Our ultimate goal is to predict CNS drug effects, in terms of time course and variability, following different dosage regimens, under a variety of physiologic and pathologic conditions. [30] [31] [32] The use of mechanism-based PK/PD modeling in in vivo preclinical studies is anticipated to provide key knowledge for prediction and thereby optimization of the therapeutic regimens of CNS drugs. 33 The simplified relationship among plasma PKs, biophase PKs, receptor occupancy, receptor activation, and effect is shown in Figure 1 .
PK/PD Modeling
The model most generally used in PK/PD modeling for a direct (no time delay) and reversible concentration-effect relationship is the Sigmoid E max model:
in which E 0 is the baseline response, E is the response observed for a given concentration at time t, C, E max is the maximal effect of the drug, EC 50 is the plasma concentration of the drug that produces 50% of E max and h is the Hill coefficient, which determines the steepness of the concentration-effect relationship.
The sigmoidal E max equation used to fit a plasma concentration-effect profile provides estimates of EC 50 and E max values that result from the combined ability of the drug to bind to its receptor (the affinity of the agonist) and the ability of the drug to cause an effect after binding to the receptor (the efficacy of the agonist). Actually, it may estimate identical EC 50 and E max values for a drug with high affinity and low efficacy and a drug with low affinity and high efficacy. It, therefore, lacks the power to predict drug responses under different physiologic or pathologic conditions, where both affinity and efficacy may be affected.
To predict the intrinsic activity and potency of a drug for a particular pharmacological effect or response, a model is required that explicitly distinguishes between drug-specific and system-specific properties. To that end, derived from the receptor occupation theory, the operational model of agonism seems to be very useful 34, 35 : 
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This equation is used to analyze agonist concentrationeffect curves in terms of the concentration of the drug (agonist) at time t, C, the baseline response E 0 , the maximal tissue response (Em), the slope of the transducer function (h), the agonist-receptor dissociation equilibrium constant (K A ), and the efficacy parameter (t). The efficacy parameter:
is expressed in terms of the total number of available receptors R 0 and the concentration of the number of receptors occupied at the half-maximal effect K E. Figure 2 shows the drug-specific and tissue-specific properties and the property that is the result from both drug and tissue, K E . Receptor affinity and intrinsic efficacy, the ÔÔdrug-specificÕÕ properties, can be estimated in in vitro bioassays, with the maximal response of the drug:
and the concentration at half-maximal response of the agonist:
The operational model of agonism has been successfully applied in numerous in vitro studies, and it has been shown recently that this approach can also be used for PK/PD analysis of in vivo drug effects. 3 For example, affinity and efficacy values of agonists at cardiac adenosine A 1 receptors have been estimated based on in vivo data and appeared to be highly consistent with estimates from in vitro radioligand-binding studies. 36 .
To estimate the parameters in the operational model, simultaneous analysis of different PK/PD relationships must be performed. These different PK/PD relationships may be obtained for one agonist under control conditions and conditions in which the number of receptors available for binding is reduced. This can be achieved by a compound that irreversibly binds to the receptor to such an extent that the agonist is no longer able to produce its maximal effect. 37, 38 Alternatively, simultaneous analysis of the PK/PD relationships that result from a series of drugs with varying degrees of agonism for the specific receptor can be used. 3 
Biophase PKs
In general, for PK/PD modeling, mostly only plasma PK data are used. However, for CNS drugs, biophase PKs
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may differ significantly from plasma PKs, because BBB transport and brain distribution often do not occur instantaneously and to a full extent. 39 This may result in a delay of the pharmacologic effect versus time profile relative to the plasma profile. For a single drug, incorporation of a hypothetical biophase concentration is an approach to take the time delay into account. This hypothetical biophase concentration is linked to the plasma concentration by a first-order rate constant for influx k 1e and a rate constant k eo for drug efflux from the hypothetical compartment. However, in the operational model of agonism, the different drugs may have significant differences in time delay between plasma and biophase kinetics. The operational model of agonism does not take into account timedependent factors, like biophase distribution. Because it is the biophase concentration that is related to the effect, biophase kinetics should be taken into consideration in using the operational model of agonism.
Factors That Govern Biophase Kinetics of CNS Drugs
The biophase kinetics of a CNS drug are governed by plasma PKs, as well as by the kinetics of BBB transport and processes of distribution and elimination within the brain.
1,2
Plasma PKs
After administration, drugs are distributed in body compartments. This occurs either in the free form or associated with 1 or more binding sites, such as plasma proteins. These binding processes vary in rate and extent, and in plasma they determine the time-dependent fraction of a drug that is available for transport into the brain. [40] [41] [42] [43] [44] [45] [46] The ÔÔfree-drug hypothesisÕÕ states that it is the free fraction of the drug that is able to pass membranes and to interact with its target.
BBB Transport
Drug transport across the BBB 47 is determined both by BBB characteristics and by the physicochemical properties of the drug. [48] [49] [50] [51] [52] [53] [54] The BBB is located at the brain capillary endothelium and is characterized by the presence of narrow tight junctions, a low rate of vesicular transport, lack of fenestrations and intercellular clefts, and a continuous basal lamina. 55 Moreover, the brain endothelial cells express numerous influx and efflux transporters.
14,17 Passive transport (diffusion) across the BBB can be either permeabilitylimited or cerebral blood flow-limited and depends on size, charge, and lipid solubility of the drug. Permeability-limited BBB transport is applicable for the more hydrophilic drugs that depend on the paracellular route for entrance into the brain (and vice versa). This paracellular route is restricted by the presence of the tight junctions between the brain endothelial cells. For the passage of these tight junctions, the size of the drug appears to be important. 50 Lipophilic, small, and noncharged drugs more easily diffuse transcellularly, and for these drugs the cerebral blood flow may become the determinant in (mainly) the rate of transport across the BBB. Active transport across the BBB occurs by receptor-mediated transport and endocytosis 14 and by numerous polarized transport systems, [56] [57] [58] such as the multidrug-resistance efflux pump P-glycoprotein 26, 27, [59] [60] [61] [62] [63] and some members of the family of MRPs. A broad range of drugs has interaction with these active transporters. 64 
Brain Distribution
The brain cannot simply be viewed as a homogeneous tissue, because it is composed of many anatomic structures with different characteristics. [65] [66] [67] In general terms, the main compartments are the brain ECF, the brain intracellular space, and the cerebrospinal fluid (CSF). After passage of the BBB, a drug enters the brain ECF and may thereafter distribute into brain intracellular space and the CSF.
2,68-72
Brain intracellular distribution is, in general, quantitatively more profound for the more lipophilic drugs and renders their extracellular brain concentrations relatively lower. Many CNS active drugs have their target at extracellular recognition sites, and, therefore, for those drugs, the extracellular brain concentrations are most closely related to the biophase concentrations.
The interplay between the kinetics of BBB transport and intracellular distribution determines the time to equilibrium between plasma and biophase kinetics. With regard to the extracellular brain concentrations, active transport out of the brain decreases whereas brain tissue binding increases the time to equilibrium. It should be noted that, other than BBB transport, active transporters may also play a role in intracellular distribution in the brain as indicated by the recent findings of localization and functional expression of a number of transporters (Pgp and MRP) in the brain parenchyma. 71 Once within the brain, other than metabolism, 73 the kinetics of drug exchange between brain ECF and CSF should also be considered. Diffusion between brain ECF and CSF is governed by the concentration gradient across the layer of ependymal cells that separates the brain ECF from the CSF. 74 In relative terms, after systemic administration of a drug, only small concentration gradients occur between brain ECF and CSF when transcapillary passage is rapid compared with CSF turnover, 75 whereas the situation is reversed for drugs with permeability-limited BBB transport. For these compounds, significant concentration gradients between brain ECF and CSF exist after systemic administration.
Pathologic Conditions
An important feature is that the BBB is under continuous physiologic control by surrounding astrocytes, pericytes, neurons, and plasma components. 17 Altogether, these factors determine the delicate homeostasis of the brain environment. This dynamic regulation of the BBB indicates that different situations may result in different BBB functionalities. Thus, it is known that BBB functionality changes on pathologic conditions. 23, [74] [75] [76] [77] [78] 80, 81 It is also expected that BBB functionality changes in CNS pathologies that include neurodegenerative processes. When, indeed, changes in BBB functionality occur, they may influence drug transport across the BBB and, therefore, they may have important implications for the biophase kinetics (Figure 1 ).
Current Project Themes
At the Fourth International Symposium of Microdialysis in Drug Research and Development, the following research project themes were presented. Here, the current state is described.
The Evaluation of the Free-Drug Hypothesis
Protein binding can have a major impact on the PKs and PDs of a drug. Drug effects, side effects, and toxic effects are generally assumed to be correlated with free-drug concentrations in plasma. 82, 83 It has been suggested that only the free drug in plasma is available for transport across the BBB 87 and determines the in vivo drug effects (free-drug hypothesis). This, indeed, holds for drugs such as benzodiazepines, certain opioids, and steroids. 6, [85] [86] [87] However, there are indications that for certain drugs, the total rather than the free concentration determines the pharmacological effect.
36, 45 The aim of this project is to develop a theoretical model for the prediction of the role of plasma protein binding as a determinant of in vivo drug effects. To this end, in vivo PK/PD experiments are performed in rats using drugs with varying degrees of plasma protein binding. 93 The special role for microdialysis in this project is that the free fraction of the drug in blood can be monitored in vivo as a function of time and concentration.
The main focus is the direct competition between plasma protein binding and receptor binding (Figure 3 
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experimentally induced changes in plasma protein binding. The values for plasma protein binding are obtained via combination of total blood concentration, ultrafiltration, and blood microdialysis measurements. The (biomarker of) in vivo b-adrenoceptor binding is analyzed in conjunction with in vitro receptor binding to establish a mechanismbased PK/PD model.
The Role of BBB Transport in the Central Effects of Opioids
Opioids are used in anesthesia, analgesia, and treatment of drug abuse. The usefulness of an opioid for a particular application is determined by its biophase kinetics and receptor binding properties. For the centrally mediated effects of opioids, plasma PKs, BBB transport, 61, 76, [88] [89] [90] [91] [92] [93] [94] [95] [96] and brain distribution determine the biophase kinetics. The objective of this project is to develop a mechanism-based PK/PD model for the central effects of opioids, taking into account the role of BBB transport. The changes in the 0.5 to 4.5 Hz frequency band of the electroencephalogram (EEG) are used as a PD end point in rats and are monitored continuously.
Previously, the EEG effects of the opioids alfentanil, fentanyl, and sufentanil have been subjected to mechanismbased PK/PD analysis, using the operational model of agonism. 6 However, the extent of the Na-shifts on the in vitro OP 3 receptor binding as a measure of efficacy did not predict in vivo efficacies of these opioids. Moreover, alfentanil, fentanyl, and sufentanil all appeared to behave as high-efficacy (full) agonists. This means that for the development of a mechanism-based PK/PD model for the central effects of opioids, additional PK/PD data on lowefficacy (partial) agonists are needed, as well as information on the biophase equilibration. Therefore, also data on nalbuphine, butorphanol, morphine, and loperamide are included in the data analysis. It is anticipated that this selected set of opioids differ widely in BBB transport characteristics and intrinsic efficacy at the OP 3 receptor.
In vitro transport characteristics, such as passive permeability rates of membrane transport and Pgp interaction, were also included. Studies were performed with cell systems comprised of epithelial cells transfected with either the human MDR1 or the rodent MDR1a gene. The results of these investigations confirmed that morphine and loperamide are substrates for Pgp and that their transport could be inhibited by the Pgp inhibitor GF120918. On the other hand, alfentanil, fentanyl, and sufentanil were found to be inhibitors, although they could not be identified as substrates for Pgp. No interaction with Pgp was observed for butorphanol. In addition, for alfentanil, fentanyl, sufentanil, and butorphanol, the passive permeability across the monolayers was very high, whereas for morphine, nalbuphine, and loperamide, the passive permeability was low. 97 In vivo, the effect of the Pgp inhibitor GF120918 on the EEG effects of morphine indicated that Pgp-mediated efflux at the BBB has an important role in the central effect-time profile of morphine. To quantitatively determine the influence of BBB transport on the PK/PD relationship of morphine, including Pgp mediated efflux, the combined EEG/microdialysis technique has been developed and used. 98 All of the data on the opioids are currently mathematically analyzed to ultimately develop the mechanism-based PK/PD model for the central effects of opioids.
Changes in BBB Transport and Biophase Equilibration of Anti-epileptic Drugs
Up to 30% of people with epilepsy continue to experience seizures, despite the best available treatment with antiepileptic drugs. The causes and mechanisms underlying intractable epilepsy are still elusive and may depend on inadequate drug concentration in crucial brain areas. [99] [100] [101] [102] [103] It is of importance to have knowledge on the implications of epilepsy-induced alterations in transporter expression, transporter functionality, ultrastructure, and permeability of the BBB in relation to transport of the different antiepileptic drugs to their targets in the brain. Such knowledge will provide crucial insight into factors that play a role in intractable epilepsy.
For a long time, it has been known that the ultrastructure and permeability of the BBB are changed by epileptic seizures. [104] [105] [106] Furthermore, recently, strong indications have become available on changes in the expression of a variety of active efflux transporters of the BBB during epilepsy. 107 However, a truly quantitative and time-dependent evaluation on the impact of changes in BBB transport mechanisms on the availability of anti-epileptic drugs around the brain target (biophase) is lacking. Biophase concentrations are crucial in the effectiveness of anti-epileptic drug treatment of epilepsy or lack of treatment effects in the pharmacoresistant portion of the epilepsy patients. It is anticipated that a quantitative characterization of the changes in individual transport mechanisms of the BBB will lead to a better understanding of the relation between anti-epileptic drug dosing and effects in different stages of epilepsy. 33 In this project we investigate the changes in BBB functionality as induced by seizures and epileptogenesis, including the time course of the development of these changes in rats. Furthermore, we make a distinction between structural and transient changes by acute seizures and the disease progression. This information will be used to develop mechanism-based PK/PD models 
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that include changes induced by seizure activity and epileptogenesis.
To assess the mechanisms of changes in BBB functionality, we include drugs with limited brain access. In this way, both increases and decreases in brain penetration can be detected. The extracellular drug concentrations in the brain are determined by intracerebral microdialysis. To study the influence of seizure activity per se on the BBB transport, the direct cortical stimulation is used, because this method allows an accurate control of the timing, frequency, and intensity of epileptic activity. 108, 109 The first results were obtained for gabapentin. A 4-compartment PK model was developed to describe the available literature data on gabapentin PKs in plasma and the extracellular and intracellular compartment of the brain in the rat. 8, 110, 111 This model was used to simulate the effect of a 1-hour increase in BBB permeability at different time points after intravenous administration of gabapentin. These in silico investigations were performed in parallel with a pilot in vivo experiment in which BBB transport of gabapentin was investigated after an intravenous bolus dose of 50 mg/ kg at time zero. Cortical dialysate was obtained from control rats and from rats that were electrically stimulated on the cortex at time zero to have a generalized seizure. The resulting plasma and dialysate concentration-time profiles of gabapentin are shown in Figure 4 . The ratio of areaunder-the-curve values in dialysate over those in plasma was 20% higher in the generalized seizure rats, indicating an increase in BBB transport for gabapentin. A full study on BBB transport changes of gabapentin on repetitive induced seizures has been performed recently, and the results are pending analysis.
The Relationship Among Neurodegeneration, BBB Transport, and Drug Effects in ParkinsonÕs Disease Progression Current treatment of ParkinsonÕs disease is still largely focused on symptom alleviation using dopamine-replacing agents, based on the fact that degeneration of nigrostriatal dopamine neurons is the primary histopathological feature of ParkinsonÕs disease. However, herewith, the underlying neurodegenerative processes are left unattended. Our research efforts are, therefore, directed toward understanding the pathogenesis of ParkinsonÕs disease to provide knowledge that will contribute to a more effective therapy that will slow down the natural progression (neurodegeneration) of ParkinsonÕs disease.
It has been posed that excitotoxicity plays a role in neurodegenerative processes via excessive stimulation of, particularly, the N-methyl-D-aspartate receptor by glutamate or NMDA agonists.
111 Anti-Parkinsonian drugs should, therefore, preferably also include neuroprotective properties. [113] [114] [115] Polyamines have a number of functions in the brain, [116] [117] [118] [119] and it is known that these endogenous compounds play an important role in excitotoxicity. 120, 121 Because BBB functionality is also influenced by polyamines, a relationship among neurodegeneration, polyamines, and BBB function [122] [123] [124] is indicated. It is, therefore, hypothesized that BBB functionality in ParkinsonÕs 
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disease is influenced by the neurodegenerative processes in disease progression.
The objective of this project is to quantify potential changes in BBB transport and effects of anti-Parkinsonian/ antineurodegenerative drugs in different stages of ParkinsonÕs disease, based on the current golden standard ex vivo histopathological markers, and to investigate extracellular polyamine levels as potential biomarkers of in vivo neurodegenerative disease progression.
At the start of the project, we selected the subcutaneous rotenone model as a rat model of ParkinsonÕs disease. 125 It has been reported that this new model more closely resembles ParkinsonÕs disease in humans than other models thus far. Betarbet et al 125 indicated that about 50% of the rotenone-treated rats developed Parkinsonian signs based on ex vivo histopathologic staining of tyrosine-hydroxylase in relevant brain areas, whereas the other rats either had no such signs or died. In our hands, only 5% of the rotenonetreated rats were positive on this marker, whereas the majority of rats suffered severely from apparent systemic toxicity, and a few died. This means that the data observed so far, such as BBB transport of the permeability marker fluorescein, 126 cannot be attributed to mechanisms in ParkinsonÕs disease. For this reason, we discontinued the use of this particular model. Currently, we are trying, as an alternative approach, the intracerebral injection of rotenone, for which the very first results are encouraging.
CONCLUSIONS
It is anticipated that the use of mechanism-based PK/PD modeling will improve the characterization and prediction of CNS drug responses in both physiologic and pathologic conditions. In vivo studies on mechanism-based PK/PD modeling of CNS drugs should include the biophase PKs, because this may differ importantly from plasma PKs by factors, such as transport, across the BBB and brain distribution processes. Microdialysis is of special value in the determination of extracellular biophase PKs, whereas it can also be used for monitoring extracellular biomarkers of drug response or disease.
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